N@N

POZEN to Present at The UBS Specialty Pharmaceuticals Conference

^{Published on 2011-06-15 04:35:49 - Market Wire}
 

CHAPEL HILL, N.C.--([ BUSINESS WIRE ])--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that [ Elizabeth Cermak ], the Companya™s Executive Vice President and Chief Commercial Officer, will participate in the UBS Specialty Pharmaceuticals Mini 1x1 Conference on Monday, June 27, 2011 in Boston.

About POZEN

POZEN Inc. is a progressive pharmaceutical company that is transforming how the healthcare industry addresses unmet medical needs. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products in two years a" something almost no other small pharmaceutical company has done. Funded by these two milestone/royalty streams, POZEN is now creating a portfolio of cost-effective, evidence based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI toxicity. The lead candidate, PA32540, is being investigated for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced ulcers and has entered Phase 3 clinical trials. POZEN is retaining commercial control of the pipeline assets and will develop a 21^st century sales and marketing organization using a new sales force model and digital communications. The Company's common stock is traded on The NASDAQ Stock Market under the symbol "POZN". For more detailed company information, including copies of this and other press releases, please visit: [ www.pozen.com ].